Jordan Dubow's guest appearances

Jordan Dubow

Empowered Patient Podcast

trialsitenews's podcast

Amolyt Pharma

Sonny Hsiao

Hartmut Ehrlich

Mark Erlander

Patricia Carter

Amanda Lucero

Wyatt West

Teresa Quattrin

Patrick Girondi

Ron Bercume

Bella Madan

Kathleen Aller

Arsen Marsoobian

Sameer Berry

Ryan Mathis

OwlTail

Discussion with Dr. Jordan Dubow, about addressing the unmet need in the narcolepsy treatment landscape. Dr. Dubow has an impressive track record working in research, in the clinic, in health systems, in biotech companies, an impressive array of medical and research experience with an emphasis on neurology and vascular neurology. Check out Avadel Pharmaceuticals here

Discussion with Dr. Jordan Dubow, about addressing the unmet need in the narcolepsy treatment landscape. Dr. Dubow has an impressive track record working in research, in the clinic, in health systems, in biotech companies, an impressive array of medical and research experience with an emphasis on neurology and vascular neurology. Check out Avadel Pharmaceuticals <a href="https://www.avadel.com/" rel="nofollow" target="_blank">here</a>

Dr. Jordan Dubow Addressing the Unmet need in the Narcolepsy Treatment Landscape

Jordan Dubow Avadel

Dr. Jordan Dubow, Chief Medical Officer, Avadel Pharmaceuticals, intent on improving drug delivery technology, is focusing on narcolepsy, a disease that causes severe excessive sleepiness and in many cases cataplexy.  While there seems to be a genetic predisposition for narcolepsy, like many neurological diseases, this rare disease is difficult to diagnose with medicines that treat daytime sleepiness and cataplexy episodes presenting significant limitations.  Avadel's once-nightly FT218 is an extended release long acting version of sodium oxybate that treats both features of the disease and allows patients to get a full night sleep without need for middle of the night dosing. @AvadelPharma #narcolepsy #SleepDisorder #EDS #cataplexy Avadel.com Download the transcript here.

Dr. Jordan Dubow, Chief Medical Officer, Avadel Pharmaceuticals, intent on improving drug delivery technology, is focusing on narcolepsy, a disease that causes severe excessive sleepiness and in many cases cataplexy.  While there seems to be a genetic predisposition for narcolepsy, like many neurological diseases, this rare disease is difficult to diagnose with medicines that treat daytime sleepiness and cataplexy episodes presenting significant limitations.  Avadel's once-nightly FT218 is an extended release long acting version of sodium oxybate that treats both features of the disease and allows patients to get a full night sleep without need for middle of the night dosing. @AvadelPharma #narcolepsy #SleepDisorder #EDS #cataplexy <a href="http://avadel.com" rel="noopener nofollow" target="_blank">Avadel.com</a> <a href="http://empoweredpatientradio.com/once-nightly-treatment-for-narcolepsy-and-other-sleep-disorders-with-dr-jordan-dubow-avadel-pharmaceuticals-transcript" rel="noopener nofollow" target="_blank">Download the transcript here.</a>

Once Nightly Treatment for Narcolepsy and Other Sleep Disorders with Dr. Jordan Dubow Avadel Pharmaceuticals